Gallbladder and Biliary Tract Disease News

 
 
  • Some Cirrhosis Deaths Have Moved Out of the Hospital Although in-hospital mortality for patients with cirrhosis has been on a downward trend, at least part of that decrease appears to have been paid for by an increased risk of death in the 30 days immediately following hospital discharge, according to a U.S. study.
  • Statins Safe in NASH Statin therapy is safe for diabetic and prediabetic individuals with nonalcoholic steatohepatitis (NASH), and should be encouraged, given these patients’ high risk of cardiovascular disease, researchers say.
  • ILC Navigating the Hep C Treatment and Cancer Risk Minefield Contradictory findings are driving disagreement over liver cancer risk after treatment with direct-acting antivirals for hepatitis C, and experts are shedding light on the way forward.
  • Extracellular Vesicles in Bile Promising Biomarker for Malignant Biliary Stenoses The concentration of extracellular vesicles (EVs) in bile can be used as a biomarker to differentiate malignant from nonmalignant common bile duct stenoses, researchers report.
  • Anticoagulant Use, Better PVT Outcomes in Cirrhosis Patients Use of anticoagulant drugs is associated with improved recanalization and slower progression of portal vein thrombosis (PVT) in cirrhosis patients, as well as to a reduced risk of variceal bleeding, according to a new systematic review and meta-analysis.
  • ASCO Biliary Tract Cancer Data 'Will Change Practice Overnight' Results from a British study of adjuvant chemotherapy that began 10 years ago could lead to an overnight change in clinical practice, says an expert.
  • U.S. Hepatitis C Cases Soar on Spike in Heroin Use U.S. health officials said new cases of hepatitis C rose nearly 300 percent from 2010 to 2015, despite the availability of cures for the liver disease, fueled by a spike in the use of heroin and other injection drugs, according to a report released on Thursday.
  • Gene Variation Predicts Recovery in Decompensated Hep C Genetic differences that are associated with recovery in patients with hepatitis C and decompensated cirrhosis who achieve a sustained virologic response could someday guide liver transplantation.
  • ILC Fecal Transplant Safe for Hepatic Encephalopathy For the first time, a clinical trial has shown that fecal transplantation can ease the decline in brain function that can result from liver failure; and the effectiveness surprised researchers.
  • ILC New System Detects Cirrhosis in Fatty Liver Disease With up to 40% of patients in primary care in the US and Europe affected by fatty liver disease, identifying who will develop fibrosis or cirrhosis is a challenge, but a new strategy appears to help.
  • ILC Comparison Backs Bezafibrate for Biliary Cholangitis For people with primary biliary cholangitis who inadequately respond to ursodeoxycholic acid, adjunctive treatment with bezafibrate increases response rates and improves symptoms, a new trial shows.
  • ILC Albumin Improves Survival in Decompensated Cirrhosis A new study answers an old question by showing that adjunctive albumin improves survival and reduces complications in patients with decompensated cirrhosis.
  • 8-week Sofosbuvir-velpatasvir-voxilaprevir Less Effective for HCV For patients with chronic hepatitis C virus (HCV) infection, eight weeks of combined sofosbuvir-velpatasvir-voxilaprevir may not be as effective as 12 weeks of only sofosbuvir-velpatasvir, results from two phase 3 open-label trials suggest.
  • NASH: The Next Untapped Pharma Market Gives Investors Many Options Large drugmakers with piles of cash are on the hunt for promising medicines being developed by small companies to treat non-alcoholic steatohepatitis (NASH), a progressive fatty liver disease poised to become the leading cause of liver transplants by 2020.
  • ILC Hep C Treatment Triumph Drives Broader Focus for ILC 2017 Clinical trial results for biliary cirrhosis and hepatocellular carcinoma are highly anticipated at the upcoming International Liver Congress (ILC).
  • Worse Waitlist, Liver Transplant Outcomes for 18- to 24-Year-Olds Compared with younger and somewhat older liver transplant candidates, 18- to 24-year-olds have poorer waitlist and posttransplant outcomes, researchers in Seattle say.
  • National Academies: How to Eliminate Hep B, C in US by 2030 The National Academies report says most hepatitis B and C infections could be eliminated by 2030 with greater vaccination and treatment.
  • Increased Mortality With Moderate, Severe Hep C-related Liver Disease Mortality is increased in patients with moderate or severe liver disease related to chronic hepatitis C, and progression from mild/moderate to severe disease cannot be predicted reliably, according to the ALIVE study.
  • Yellow Fever Vaccine Advised for Travel to Brazil's Rio, Sao Paulo States The World Health Organization on Monday recommended that travelers to rural areas in the states of Rio de Janeiro and Sao Paulo get yellow fever vaccinations, as Brazil works to contain an outbreak of the virus in the country's southeast.
  • DUPC Nonalcoholic Fatty-Liver Disease Doubles Death Rates in Diabetes Nonalcoholic fatty-liver disease increases the risk of death from cancer and other causes, as well as the risk of cardiovascular events, in patients with type 2 diabetes, reveals a population-based study.